Breast cancer five-year survival can be predicted without tissue imaging: HEAL-Surv lifts concordance from 0.658 to 0.704 by distilling a teacher
HEAL-Surv puts imaging mass cytometry (IMC, which measures protein markers per cell while keeping cell positions) and DNA methylation into a teacher used only during training, so a student predicts five-year net disease-specific survival in breast cancer from molecular and clinical inputs alone at inference. In five-fold cross-validation on 423 METABRIC patients, distillation raised the matched student's mean five-year Uno's concordance from 0.658 to 0.704, while the integrated and five-year Brier scores both rose.